News

TD SYNNEX Reports Strong Q3 Results: Positive Growth Trends

TD SYNNEX Reports Strong Q3 Results: Positive Growth Trends

Strong Financial Performance in Q3

TD SYNNEX Corp (NYSE: SNX) recently announced its third-quarter financial results, showing a notable performance that exceeded expectations. Following the report, shares of the company experienced an uptick, indicating investor confidence.

Earnings and Revenue Highlights

During the third quarter, TD SYNNEX reported an adjusted earnings per share (EPS) of $2.86, which surpassed the anticipated figure of $2.80. This remarkable performance has drawn positive attention from analysts and stakeholders alike.

The company achieved quarterly revenue of $14.69 billion, marking an impressive 5.2% year-over-year (Y/Y) increase. This figure also exceeded analyst predictions, which estimated revenue around $14.11 billion. When adjusted for constant currency, revenue growth stood at approximately 5.6%, driven by advancements in both the Advanced Solutions and Endpoint Solutions sectors.

Gross and Operating Margins

TD SYNNEX also saw adjusted gross billings reach $20.3 billion for the quarter, a significant jump from $18.58 billion in the same period last year. While adjusted gross profit for the current quarter was reported at $961.05 million—down slightly from $973.7 million in the prior year—the gross margin remained competitive at 6.54%, although it has dipped from 6.97%.

In terms of adjusted operating income, TD SYNNEX reported $393 million, which is a marginal decrease compared to $397 million from the previous year. This translates to an operating margin of 2.7%, down from 2.8% year-over-year.

Commitment to Shareholders

In a show of commitment to its shareholders, TD SYNNEX returned $91 million through share repurchases and dividends. The Board of Directors declared a quarterly cash dividend of $0.40 per common share, which is set to be payable soon to stockholders who are on record as of a specified date.

Future Projections

Looking ahead, TD SYNNEX projects an adjusted EPS for the fourth quarter in the range of $2.80 to $3.30, slightly higher than the estimated $3.22. Additionally, the company forecasts revenue between $14.9 billion and $15.7 billion, surpassing expectations of about $15.15 billion.

Market Outlook

Patrick Zammit, the CEO of TD SYNNEX, expressed optimism regarding the IT market recovery. He highlighted significant growth across different geographic segments and in both the Endpoint and Advanced Solutions divisions, with gross billings seeing a 9% rise, exceeding previous projections.

Investment Opportunities

Investors seeking to gain exposure to TD SYNNEX can consider options such as the Invesco Exchange-Traded Fund Trust II Invesco S&P MidCap 400 Revenue ETF (NYSE: RWK) and the Invesco S&P Midcap 400 Pure Value ETF (NYSE: RFV).

Recent Price Activity

As for the market performance, shares of TD SYNNEX (SNX) saw an increase of 2.17%, trading at approximately $119.84 during the most recent market check.

Frequently Asked Questions

What are TD SYNNEX's Q3 earnings?

TD SYNNEX reported an adjusted EPS of $2.86 for Q3 2024, beating expectations.

How much revenue did TD SYNNEX generate in Q3?

The company generated $14.69 billion in revenue, a 5.2% increase from the previous year.

What is TD SYNNEX's outlook for Q4?

TD SYNNEX expects an EPS of $2.80 to $3.30 and revenue between $14.9 billion and $15.7 billion for Q4.

What dividends did TD SYNNEX declare?

The Board declared a quarterly cash dividend of $0.40 per common share payable soon.

What investment options are available for TD SYNNEX?

Investors can explore the Invesco S&P MidCap 400 Revenue ETF (RWK) and Invesco S&P Midcap 400 Pure Value ETF (RFV) for indirect exposure.

About The Author

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.

Top 10 Most Recent News Articles

Regeneron Faces Legal Heat: Lead Plaintiff Deadline Looms

Updated Category News Views 5

Regeneron’s Tight Spot: Legal Showdown Well, here we go again—Regeneron Pharmaceuticals (NASDAQ:REGN) is under some serious heat. If you're an investor who faced significant losses with this biotech juggernaut, remember that the clock’s ticking down to the wire. By tomorrow, September 14, 2026, you need to decide if you're going to throw your hat in the ring for...

Continue Reading
Tam-Peli Steps Up in SCLC Battle: Trial Insights

Updated Category News Views 5

Noteworthy Developments in Small-Cell Lung Cancer Treatment Let's dive into a story straight from the world of small-cell lung cancer (SCLC) that doesn't take any prisoners. The antidote making waves is tambotatug pelitecan, or Tam-Peli for short, showcasing its might in the unrelenting fight against relapsed SCLC. The phase III TAISHAN-302 trial puts Tam-Peli...

Continue Reading
PANDAG G1 Debuts: Revolutionizing Lawn Care Efficiency

Updated Category News Views 4

The Future of Landscaping Unveiled Get this—PANDAG is set to shake things up at GaLaBau 2026 with their futuristic G1 autonomous mower. This isn't just another piece of lawn equipment; it's practically a tech marvel on wheels, weaving together LiDAR, AI Vision, RTK, and 4G tech to make it the ultimate multitasker for the landscaping industry. We're talking obstacle...

Continue Reading
First-Time Homeowners: Unseen Pitfalls of Insurance

Updated Category News Views 6

Understanding Homeowners Insurance: Beyond the Basics Most folks diving into homeownership for the first time get caught up in the whirlwind of price tags, loans, and knick-knacks for their new place. Meanwhile, the nitty-gritty of homeowners insurance often gets tossed to the side. But take it from a weary watchdog of financial storms—it’s those details in the policy...

Continue Reading
UWM Faces Class Action Deadline: Key Insights for Investors

Updated Category News Views 2

The High Stakes Reality for UWM Investors If there's one thing that's certain in this jittery world of investing, it's that losses have a way of waking you up. Right now, anyone tied up with UWM Holdings Corporation (NYSE: UWMC) shares needs to keep their wits about them; we're barreling toward an October 13, 2026 deadline for a class action lawsuit. The clock's ticking...

Continue Reading
Surfing Dogs Ride Waves, Support Orphan Pets

Updated Category News Views 3

Waves, Paws, and Passion Who would've thought that dogs catching waves could also catch hearts and wallets? Well, that's exactly what's happening today at Del Mar Dog Beach with the 21st Annual Surf Dog Surf-A-Thon revving up the excitement. It's a sun-soaked day in Rancho Santa Fe, California, right in the thick of things at the longest-running dog surf competition. For...

Continue Reading
Ris-Rez May Set New Standard in Relapsed SCLC

Updated Category News Views 6

The Game-Changing Results Innovation in pharmaceuticals sometimes feels like a waiting game, but when a fresh breakthrough like this rolls in, it lights up the whole landscape. Risvutatug rezetecan, or Ris-Rez for short, has shown promising potential in the fight against relapsed small-cell lung cancer (SCLC) that has progressed after platinum-based therapy. Survival...

Continue Reading
Trial Disappointment: No Significant Gains in NSCLC

Updated Category News Views 12

Dissecting the Nuances of the EVOKE-03/KEYNOTE-D46 Trial Every once in a while, we come across a trial that rattles cages in the research community. Today, it's the EVOKE-03/KEYNOTE-D46 trial, a collision of hope and hard-knock reality. This Phase 3 trial, which sought to explore the potential combo of sacituzumab govitecan (SG) and pembrolizumab on metastatic non-small...

Continue Reading
PwC US and India Unite for Global Consultancy Powerhouse

Updated Category News Views 7

Rearranging the Consultancy Chessboard Piling onto the game of consultancy realignments, PwC just made a move reminiscent of playing strategy poker. They're tossing together PwC US and PwC India's advisory capabilities for a new joint venture. It’s like pushing two puzzle pieces to make a single colorful picture that stretches from the U.S. all the way to the...

Continue Reading
GORGIE Unleashes Berry Burst: Target's New Drink Star

Updated Category News Views 5

GORGIE Targets Taste Buds with Berry Burst Ever feel like you're missing out on that energy drink everyone seems to be raving about? Well, GORGIE's out there making some noise again, and this time it's got a new punchy player in the game: Berry Burst. It's not just another drink; it's shaking things up in the energy aisle with its exclusive launch at Target. Modern style...

Continue Reading

Top 5 Most Recently Viewed Articles

Innovative Smart Living Solutions Unveiled by Hisense at CES 2026

Updated Category News Views 136

Hisense Unveils Smart Living Innovations at CES 2026 Hisense has made headlines once again at CES 2026 by presenting an impressive array of smart living solutions that integrate seamlessly into everyday life. The company, recognized worldwide for its prowess in consumer electronics and home appliances, demonstrated its commitment to enhancing modern living through...

Continue Reading
Exploring the Innovations of Oncotelic Therapeutics Inc.

Updated Category News Views 103

Oncotelic Therapeutics: A Leader in Cancer Innovations Oncotelic Therapeutics Inc. (NASDAQ: OTLC), a pioneering clinical-stage biopharmaceutical company, is committed to advancing groundbreaking therapies in oncology and immunotherapy. The organization specializes in developing innovative treatments for difficult-to-treat cancers and rare diseases. This vision is...

Continue Reading
Introducing EMBREY Insights: A New Perspective on Investments

Updated Category News Views 128

Introducing EMBREY Insights: A New Publication for Investors New Publication Focuses on the Emerging Strength of Multifamily Investments EMBREY, a vertically integrated real estate investment company, recently announced the launch of its latest research periodical, EMBREY Insights. This new publication aims to deliver expert research and insights on multifamily investment...

Continue Reading
Oportun's Strategic Alliance with Findell Capital Management

Updated Category News Views 105

Oportun Enters Strategic Cooperation Agreement Oportun Financial Corporation (Nasdaq: OPRT), a dedicated financial services firm, has embarked on a groundbreaking journey by entering a multi-year cooperation agreement with Findell Capital Management LLC. This collaborative move marks a significant milestone in maintaining harmonious relations within the company’s...

Continue Reading
Nutricosmetics Market Expected to Surpass $15 Billion by 2033

Updated Category News Views 174

Nutricosmetics Market Overview The global nutricosmetics market is on a trajectory for substantial growth, with projections estimating a rise from USD 8.28 billion in the near future to USD 15.36 billion by 2033. According to industry insights, this growth represents a compound annual growth rate (CAGR) of 8.07% from 2026 to 2033. The increasing awareness regarding the...

Continue Reading